Key Multiple Myeloma Abstracts Presented at 2024 ASCO and EHA Meeting скачать в хорошем качестве

Key Multiple Myeloma Abstracts Presented at 2024 ASCO and EHA Meeting

Dr. Joseph Mikhael provides a rapid overview of groundbreaking research in multiple myeloma, highlighted from ASCO and EHA conferences. Key studies focus on newly diagnosed and early relapsed patients, CAR T-cell therapies, bispecific antibodies, and immunotherapy sequencing. Key Points: Newly Diagnosed Multiple Myeloma: Phase III trials (IMROZ and BENEFIT) compare quadruplet (Ixatuzimab + VRD) vs. triplet (VRD) therapies in non-transplant eligible patients up to age 80. Significant findings include extended remission periods with quadruplet therapies, suggesting a shift towards more intensive upfront treatments. Early Relapsed Multiple Myeloma: Revival of belantamab mafodotin (BLENREP) with promising results in trials like DREAMM7 and DREAMM8. Belantamab shows superiority over daratumumab and bortezomib combinations, indicating potential re-introduction into clinical practice pending further side effect management. CAR T-Cell Therapy: Advancements in CAR T-cell therapies (e.g., cilta-cel, ide-cel) demonstrate efficacy in high-risk disease settings. Early administration of CAR T-cells shows improved outcomes, highlighting a future trend towards earlier intervention. Bispecific Antibodies: Emerging data supports less frequent dosing schedules (e.g., elotuzumab every other week) for bispecific antibodies. Reduced dosing schedules improve convenience and potentially reduce side effects, enhancing patient compliance and safety. Immunotherapy Sequencing: Ongoing studies investigate optimal sequencing of immunotherapies (CAR T-cell vs. bispecific antibodies). Individualized treatment approaches are crucial; generally, CAR T-cell therapy may precede bispecific antibody use, pending patient-specific factors. In conclusion, these findings signify a transformative era in multiple myeloma treatment, emphasizing personalized medicine and enhanced therapeutic options. For more information, visit Myeloma.org and explore resources provided by the IMF. _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.